{"name":"Shanton Pharma Pte. Ltd.","slug":"shanton-pharma-pte-ltd","ticker":"","exchange":"","domain":"","description":"Shanton Pharma Pte. Ltd. is a biopharmaceutical company focused on the development of innovative therapies. The company's lead candidate, SAP-001, is currently in Phase 2 clinical trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"SAP-001","genericName":"SAP-001","slug":"sap-001","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"SAP-001","genericName":"SAP-001","slug":"sap-001","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPcFZ3VkYtaHBTM2VuaDBqZ1gxa3RLM3JxRWd4SGpEUm1XdmcxejI0RV8xc2ZJaDBUR2NNN2hEeWx6MGdSY2V2UW15akNPbFJYYWo5ZVRDTkxQd2lobWtlNVpacldWblJiN3Q2dE9qOGZxSFpCTS0yRk55VWNDdDQxY1EtRG1NQldlM0w4M0Zrb2E5eXp6cU9YLQ?oc=5","date":"2026-01-09","type":"pipeline","source":"The Pharma Letter","summary":"BioRay Biopharmaceutical files for Hong Kong IPO | Biotechnology | The Pharmaletter - The Pharma Letter","headline":"BioRay Biopharmaceutical files for Hong Kong IPO | Biotechnology | The Pharmaletter","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxNalU3SkExSFFqNHJpRnNuQVpoTDFvV1ljeUV0cTFjQ3JUYUFlM01MbzlSZkpKMHhhaTl5OWZNU2NfR2Uwc0YtYjNTaG5YaldCRF9RZWtseDdOOElZMUNEV1Q0U3ZIelFpb0xxY1hqZ3JpbTAweWw3YzZlUk5OQ1FQUGV5OEtfRnpENkdMaUZ6UllEWFFTZjBQT1kycmZ4dTJmaHdKMG5RLWh3SzFaWGRYVVBMMDB0aWlUdlJWN0V6cnVrTTJEZUx0ZzJFNlo0Zw?oc=5","date":"2025-10-27","type":"regulatory","source":"PR Newswire","summary":"Shanton Pharma Completes EOP2 Meeting with US FDA for Refractory Gout Program - PR Newswire","headline":"Shanton Pharma Completes EOP2 Meeting with US FDA for Refractory Gout Program","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxPNEx3eVdsSzFHVi1MSUxRenZ3TnlNbHBoSVhmVFBEYnJ3V3FIX1d5TlFFNnRqSnJWZTUxc1A1V3hyQnFIYUxfcXRxMHQ1b2x4bHpNWVRGTjNwci1SQ2FLZlVpQUowdHptTkVIQnpqdTNVWk95ck45aUdfRlBYdUo1d1ozQWxEajB5RGxoTWxnNkl5Y0VGZlBYYXMzeERSR1JVZ1B3dkVOREk2TXVNWWxMTFc4RW9iWkNwVWVIYWVrY0VCX2htU3NreHFGS3NvVFRBTk52TnZQTFFYVTlyYW1kaHRteWIyQTl1ZEpMc24yRkstUktTdUg5YzVXdFlVeldVMXFMY1NOZ1o?oc=5","date":"2025-09-16","type":"trial","source":"GlobeNewswire","summary":"Gout Clinical Trial Pipeline Expands as 20+ Companies Driving Innovation in Gout Therapeutics | DelveInsight - GlobeNewswire","headline":"Gout Clinical Trial Pipeline Expands as 20+ Companies Driving Innovation in Gout Therapeutics | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxQV01IdF9MY1NieDJHSFI1eTh4YUJZbnQ1VUxyZzVscmZ2OS1PRkE2YzBvdkxPQWdGSnotU1VycVB5WkhqT1lZOEROSmlFNnp4aU53SWJZejJhWG5WSC1kYzhodGFzM1ZRSUtUWThZTDRzRG9RTFVzQWhiRFMxR2xRdFZ2VURaRTN6bjVkaVNDZlc4TzZBSFlhWnN5eGZERFVuOGFzM0lDZXRkdXZib2JPSTBlLWc5VWpYbUI5QjNNWlpRZ1pDME9NWG41NWE?oc=5","date":"2025-08-13","type":"regulatory","source":"PA Media","summary":"Shilpa Medicare's NorUDCA Makes History as First Approved NAFLD Therapy Worldwide - PA Media","headline":"Shilpa Medicare's NorUDCA Makes History as First Approved NAFLD Therapy Worldwide","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxQT3lNTXJuQ1RkUjF3QWJtR2JheTM0dFpKVUdGSGlJcUFnYzI0S21xTnZmakVIM09EbzlLSVYydF9oMXQ0SzB1UDNjMFQ3dXUxbHBWdlVXMjlXV3k5R2tKY3VJRnUyZlJPelM4aU85ZHMyZFl3REZxUkFXR2dPNzdTdVg5SnQ4VTF6bGFqLTNNQm02bkx2VC1NTG42aTdBcnhUOUx3OGJ6RTZTNFFkd3lQcWxneDRBRkwxRWlyWFV4amNNREVEdklOOHh1ZWlXdkd3?oc=5","date":"2025-07-25","type":"regulatory","source":"PR Newswire","summary":"Shanton Receives Fast Track Designation from US FDA for Refractory Gout Program - PR Newswire","headline":"Shanton Receives Fast Track Designation from US FDA for Refractory Gout Program","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxNTkNHQlN1ZjAxSXhXWGdNbEw3Mlk3TmZ3NktKSlVyYWs0VlBVMkpmYWVzM1pBMmxJUTRLR3JIRlVIT2htc3dBRzczRFE3c1JHdVlLcmh4bUZ0OEE2RnlPYURLMnVVMmpVdmZ3ckZNQXR6Q2RmX2phMVJ4WWpoS0JDcmVQVEF0U3FTNE1tSjJtaEdCWTVvNExkZDE4WmQ0dF9rVmFocXZ0VExpMWlPX0hZN3dDVm1JblhFOVZ2WEZLdUtGNUFTTjVJ?oc=5","date":"2025-03-27","type":"trial","source":"PA Media","summary":"Shanton Reveals Topline Data from Phase 2b Study in Refractory Gout Patients - PA Media","headline":"Shanton Reveals Topline Data from Phase 2b Study in Refractory Gout Patients","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTFBhRVpicnVzcUZodnFhajI4QkhRUXNhRjVXZjN4c0RpaXEzSW9BZ3pQUWRzSTQ2RXQxNFZFSDc2cVBUbFdiTzFRYzl5bk9wTF9ZZ0o4T1JQTDR5MUF6Sk45QWt6TDE4YklhWWt1ZFBhWHk2WmZlYWZkVkxR?oc=5","date":"2024-08-06","type":"trial","source":"Clinical Trials Arena","summary":"Shanton Pharma’s Phase IIb gout treatment trial reaches full enrolment - Clinical Trials Arena","headline":"Shanton Pharma’s Phase IIb gout treatment trial reaches full enrolment","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}